Founder of Genentech on the ten-minute meeting, betting that the future is now, and building the thing that doesn’t exist
Founder of Genentech on the ten-minute meeting, betting that the future is now, and building the thing that doesn’t exist
The Z Fellows Newsletter - October 26, 2026
Welcome back to the Z Fellows newsletter! Every Monday we share 3 ideas - to help you build companies, ship products, and create your life's work.
1: The ten-minute meeting
“Bob and I were very naive about how we were going to do it.” — Herbert Boyer and Robert Swanson, co-founders of Genentech
In early 1976, Robert Swanson was 28 and had recently been pushed out of his venture job. Although interviewing daily, he was still captivated by one idea: that recombinant DNA could be turned into medicine today, not in some distant future. So, he did the unglamorous thing and cold-called the scientists doing the work, hoping one would pick up.
Herbert Boyer, a UCSF biochemist, reluctantly granted him ten minutes on a Friday afternoon. Swanson’s conviction was contagious; the ten minutes stretched to hours, moved to a nearby bar over beers, and by the end the two had agreed to start a company. That company was Genentech, and that conversation founded the entire biotechnology industry. There is a life-size bronze statue of the two men at that table, mid-conversation, at Genentech’s headquarters today.
The lesson is almost embarrassingly basic: the meeting that started a hundred-billion-dollar industry happened because an unemployed 28-year-old was willing to make cold calls and ask for ten minutes. The door to the thing nobody has built is usually unlocked because nobody else is bothering to try it.
The takeaway: The most important conversation of your career may be one cold call away. The people at the frontier are more reachable than you think. Ask for ten minutes and bring enough conviction to earn the next three hours.
2: Bet that the future is now
“Everybody he talked with said it would be 15 – 20 years before that happened.” - on Swanson’s belief that recombinant DNA was commercially viable
Swanson’s real edge wasn’t access; it was a timeline disagreement. The scientific and business consensus was unanimous that turning gene-splicing into marketable products was 15 to 20 years away. Swanson looked at the same evidence and concluded it was viable immediately. The reason the Boyer meeting caught fire is that Boyer, almost alone among scientists, quietly agreed.
That single compression of the timeline was the whole company. If the technology were really two decades out, starting a firm in 1976 was madness. If it were ready now, then every year the consensus spent waiting was a year Genentech had the field to itself. Within about a year, Genentech scientists produced the first human protein in bacteria; within two, human insulin.
Being right about what is possible matters less than being right about when. The consensus is often correct that something will happen and wildly wrong about how soon, and that gap between “eventually” and “now” is where the company gets built.
The takeaway: When everyone agrees a breakthrough is inevitable but far off, interrogate the timeline yourself. The richest opportunities aren’t things nobody believes in, they’re things everyone believes are further away than they really are.
3: Build the thing that doesn’t exist yet
“No one had yet recognized the potential application of the new biologically-based technology to create beneficial new products.” — Robert Swanson
When Swanson started, there was no biotechnology industry, no template for a science-driven company, and no venture playbook for any of it; the small VC world of the mid-1970s was focused entirely on electronics. So, Swanson didn’t just build a product; he built an institution from first principles. He designed Genentech to be a place where the best scientists would want to join: where they could publish freely, share in the upside, and protect their work through patents rather than secrecy.
He also pioneered the financial scaffolding a science company needs, using research-and-development partnerships to fund the work and later taking Genentech public in 1980 before it had a single product to sell. Each of these was an invention as real as the insulin.
Founders in established industries inherit the org chart, the funding norms, the way things are done. When you’re first, all of that is a design problem and getting the institution right matters as much as getting the product right because the institution is what produces every product after the first.
The takeaway:If you’re building something genuinely new, remember you’re inventing the company as well as the product. Design the incentives, the funding, and the culture deliberately; there’s no template to inherit, only one to create.
See you next Monday,
- The Z Fellows Team
Any feedback?
Want to dive deeper? Listen to our mentor interviews here.
Interested in becoming a Z Fellow? Apply here.
Update your email preferences or unsubscribe here
© 2026 Z Fellows
228 Park Ave S, #29976, New York, New York 10003, United States
Powered by beehiiv